38 results on '"O. B. Bezlepkina"'
Search Results
2. Effectiveness and safety of an artificial intelligence-based medical decision support system for adjusting insulin pump settings in children with type 1 diabetes mellitus: randomized controlled trial
- Author
-
D. N. Laptev, D. Yu. Sorokin, E. S. Trufanova, O. Yu. Rebrova, and O. B. Bezlepkina
- Subjects
diabetes mellitus ,children ,artificial intelligence ,insulin pump therapy ,clinical decision support system ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Previously, we presented the process of developing a clinical decision support system (CDSS) for adjusting insulin pump (IP) settings in children with type 1 diabetes mellitus (T1D) and assessing the agreement of the recommendations it generates with the expert opinion. The CDSS demonstrated satisfactory forecasting of glucose profile and agreement rates between recommendations CDSS and experts.AIM: To evaluate the effectiveness and safety of using CDSS in children with T1D, testing the hypothesis of non-inferiority (with a limit of -5%) of relative increase of glucose time in range (TIR) over 6 months.MATERIALS AND METHODS: The trial included 80 children with T1D, divided into two comparable groups of 40 children using the minimization method. Patients in the main group received recommendations for adjusting the IP settings from a physician who uses the CDSS; patients in the control group received recommendations from a physician (control group). Patients were observed for 6 months with remote consultations once a month (7 consultations in total) and monitoring of glycated hemoglobin (HbA1c) at 1, 4 and 7 consultations. The primary outcome is the difference in group mean relative changes in TIR (%), secondary outcomes are TIR (%), HbA1c concentration. RESULTS: The trial was completed by 63 patients 32 in the main group, 31 in the control group. The difference in the mean relative increase in TIR at the 7th consultation in the groups was 3.02%, one-sided 95% CI (-4.55%; inf ). Thus, the lower bound of this CI is greater than the noninferiority limit of -5%, and the noninferiority hypothesis can be accepted. There were no statistically significant differences between groups for all outcomes. The dynamics of the indicators were positive in the main group and had a statistical tendency towards positive changes in the control group.CONCLUSION: The use of CDSS was no less effective in terms of the TIR than the management of the patient by a physician. The use of CDSS in clinical practice can help in regular and frequent monitoring of children with T1D, and standardize at a high level the approach to correction of IP parameters, supplemented with CGM.
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical decision support system based on artificial intelligence for adjusting insulin pump parameters in children with type 1 diabetes mellitus
- Author
-
D. Yu. Sorokin, E. S. Trufanova, O. Yu. Rebrova, O. B. Bezlepkina, and D. N. Laptev
- Subjects
diabetes mellitus ,children ,artificial intelligence ,insulin pump therapy ,clinical decision support system ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Widely available diabetes devices (continuous glucose monitoring, insulin pump etc.) generate large amount of data and development of an advanced clinical decision support system (CDSS), able to automatically evaluate and optimize insulin therapy, is relevant.AIM: Development of a mathematical model and an CDSS based on it to optimize insulin therapy in children with type 1 diabetes (T1D) and assessment of the agreement between the recommendations of the CDSS and the physician on insulin pump (IP) parameters: basal profile (BP), carbohydrate ratio (CR), correction factor (СF).MATERIALS AND METHODS: Data from 504 children with T1DM were analyzed over the period of 7875 days. The data included glucose, insulin, food, sex, age, height, weight, diabetes duration and HbA1c. We constructed recurrent neural network (RNN) to predict glucose concentration for 30-120 minutes, an algorithm for optimizing IP settings using prediction results. Next, a software product was developed — a CDSS. To assess the agreement of the recommendations of the CDSS and physicians, retrospective data from 40 remote telemedicine consultations of 40 patients with T1D (median age 11.6 years [7; 15]) were used and 960 points of possible adjustments were analyzed. Three degrees of agreement have been introduced: complete agreement, partial agreement, and complete disagreement. The magnitude of the adjustments was also analyzed.RESULTS: The accuracy of glycemic predictions was better or comparable with other similar models. The assessment of agreement for BP, CR and CF, according to the Kappa index, showed slight and weak agreement. The frequency of complete agreement between recommendations for adjusting the ongoing IP therapy between the CDSS and physicians is 37.5–53.8%, and complete inconsistency is 4.5–17.4%. From a clinical point of view, consistency in the frequency of occurrence of the indicator is more important. There were no differences in median IP settings between the CDSS and physicians.CONCLUSION: The CDSS has an acceptable accuracy of glycemic predictions. The CDSS and physicians provide comparable recommendations regarding CSII parameters.
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical prediction model for MODY type diabetes mellitus in children
- Author
-
D. N. Laptev, E. A. Sechko, E. M. Romanenkova, I. A. Eremina, O. B. Bezlepkina, V. A. Peterkova, and N. G. Mokrysheva
- Subjects
diabetes mellitus in children ,mody ,monogenic diabetes mellitus ,clinical decision support system ,mody prediction model ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: MODY (maturity-onset diabetes of the young) is a rare monogenic form of diabetes mellitus, the gold standard of diagnosis is mutations detection in the genes responsible for the development of this form diabetes. Genetic test is expensive and takes a lot of time. The diagnostic criteria for MODY are well known. The development of clinical decision support system (CDSS) which allows physicians based on clinical data to determine who should have molecular genetic testing is relevant.AIM: Provided a retrospective analysis of clinical data of the patients with T1DM and MODY, from 0 to 18 years old, regardless of the duration of the disease to develop the model. Based on clinical data, a feedforward neural network (NN) was implemented - a multilayer perceptron.MATERIALS AND METHODS: Development of the most effective algorithm for predicting MODY in children based on available clinical indicators of 1710 patients with diabetes under the age of 18 years using a multilayer feedforward neural network.RESULTS: The sample consisted of 1710 children under the age of 18 years with T1DM (78%) and MODY (22%) diabetes. For the final configuration of NS the following predictors were selected: gender, age at passport age, age at the diagnosis with DM, HbA1c, BMI SDS, family history of DM, treatment. The performance (quality) assessment of the NN was carried out on a test sample (the area under the ROC (receiver operating characteristics) curve reached 0.97). The positive predictive value of PCPR was achieved at a cut-off value of 0.40 (predicted probability of MODY diabetes 40%). At which the sensitivity was 98%, specificity 93%, PCR with prevalence correction was 78%, and PCR with prevalence correction was 99%, the overall accuracy of the model was 94%.Based on the NN model, a CDSS was developed to determine whether a patient has MODY diabetes, implemented as an application.CONCLUSION: The clinical prediction model MODY developed in this work based on the NN, uses the clinical characteristic available for each patient to determine the probability of the patient having MODY. The use of the developed model in clinical practice will assist in the selection of patients for diagnostic genetic testing for MODY, which will allow for the efficient allocation of healthcare resources, the selection of personalized treatment and patient monitoring.
- Published
- 2024
- Full Text
- View/download PDF
5. Islet autoantibodies and residual beta-cell function in children with type 1 diabetes depending on age of manifestation
- Author
-
E. M. Romanenkova, I. M. Zufarova, D. Y. Sorokin, I. A. Eremina, E. A. Sechko, L. V. Nikankina, V. A. Peterkova, O. B. Bezlepkina, and D. N. Laptev
- Subjects
type 1 diabetes ,children ,manifestation ,c-peptide ,autoantibodies ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Type 1 diabetes mellitus (T1D) is an autoimmune disorder that leads to pancreatic β-cells destruction and progressive decrease of insulin secretion. Specific islet autoantibodies (AAbs) are the main diagnostic marker of T1D. Residual β-cell function, as measured by C-peptide, has repeatedly been demonstrated to be clinically important.AIM: To study the frequency and levels of residual C-peptide secretion and persistence of pancreatic AAbs in children with T1D with different duration and age of manifestation of the disease.MATERIALS AND METHODS: The levels of C-peptide and AAbs to ZnT8 (zinc transporter 8), AAbs to IA-2 (Insulinoma Antigen 2), AAbs to GAD (Glutamate Decarboxylase), IAA (insulin autoantibodies) were measured. Patients were divided into 3 groups depending on the duration of T1D (1st — 5 years) and age of manifestation (A — prepubertal and B — puberty).RESULTS: The median duration of T1D was 1.8 [0,8;3,9], 76.3% out of 1333 patients were seropositive, 40% had residual levels of C-peptide. With disease duration there were a decrease in AAbs+: 1st group 74%, 2nd group 69%, and 3rd group 48%. In all groups, percentage of patients with positive levels of one or more AAbs was significantly higher in children with T1D manifestation at puberty. GADA and ZnT8A were more common in the first year of the disease. IA-2A were observed with the same frequency in the group of adolescents. IAA were more common in patients at prepubertal age. An undetectable level of C-peptide was observed significantly higher in children with T1D manifestation in prepubertal age (p
- Published
- 2023
- Full Text
- View/download PDF
6. The role of specific pancreatic antibodies in the differential diagnosis of complete clinical and laboratory remission of type 1 diabetes mellitus and MODY in children
- Author
-
E. A. Sechko, E. M. Romanenkova, I. A. Eremina, L. I. Zilberman, L. V. Nikankina, Z. T. Zuraeva, O. B. Bezlepkina, V. A. Peterkova, and D. N. Laptev
- Subjects
type 1 diabetes ,mody ,autoantibodies ,remission ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: T1D is characterized by autoimmune destruction of pancreatic β-cells, which develops due to genetic and environmental risk factors. Shortly after initiating the treatment with insulin, 80% of children with T1D may require smaller doses of insulin and develop clinical and laboratory remission of the disease so called «honeymoon». The issue of whether there is a need of differential diagnosis between autoimmune DM and non-immune forms of DM raises in cases of preclinical diagnosis of T1D and laboratory remission for more than 6 months.AIM: To study the clinical, immunological, genetic characteristics of T1D remission phase and MODY in children, to determine the diagnostic criteria for T1D and MODY in children.MATERIALS AND METHODS: A single-centre, cross sectional noncontrolled comparative study of two independent cohorts. Data of 150 children examined in the Endocrinology Research Center (January 2016–June 2021). First cohort included patients with complete clinical and laboratory remission of T1D (n=36), second cohort included patients with MODY, confirmed by genetic study (n=114).RESULTS: The median age of diabetes manifestation was significantly higher in patients with T1D — 11.25 years [8.33; 13.78] than in patients with MODY — 7.5 years [4.6; 12.2] (p=0.004). In patients with T1D remission the level of glycated hemoglobin was 6.0% [5.6; 6.4], in group with MODY — 6.5% [6.2; 6.7] (p
- Published
- 2022
- Full Text
- View/download PDF
7. Comparison of the accuracy of resting energy expenditure assessment using bioimpedance analysis and indirect respiratory calorimetry in children with simple obesity
- Author
-
P. L. Okorokov, O. V. Vasyukova, and O. B. Bezlepkina
- Subjects
pediatric obesity ,basal metabolism ,bioimpedance analysis ,indirect calorimetry ,Physiology ,QP1-981 ,Biochemistry ,QD415-436 - Abstract
Background: Assessment of resting energy expenditure (REE) is necessary for the formation of a diet for obesity patients. The «gold standard» for assessment of resting energy expenditure (REE) is indirect respiratory calorimetry. Currently, bioimpedance analyzers are increasingly being used in clinical practice to assess energy consumption at rest, including in obese children. However, the accuracy of such an assessment remains unclear.Aims: To determine the accuracy of the assessment of resting energy expenditure using bioimpedance analysis in children with simple obesity compared with indirect respiratory calorimetry.Materials and methods: Resting energy expenditure was assessed by bioimpedance analysis, Harris-Benedict formula and indirect respiratory calorimetry in all obese children. Comparability of methods was assessed using the Bland-Altman analysis.Results: The study included 320 children aged 7 to 17 years with simple obesity.Resting energy expenditure assessed by bioimpedance analysis was on average 232 kcal lower than the actual. A significant CI (-448 to 912 kcal) was revealed, as well as a large LOA from -514 to 979 kcal. REE calculated by the Harris-Benedict formula on average corresponded to the actual one, and CI varied from -38 to 27 kcal. However, large LOA from -514 to 979 kcal, indicating a high individual variability of resting energy consumption.Conclusions: Bioimpedance analyzers underestimate REE in obese children compared to indirect respiratory calorimetry and the Harris-Benedict formula. Given the significant discrepancies in the accuracy of REE assessment, bioimpedance analysis cannot be considered as an alternative to indirect respiratory calorimetry to assess resting energy in children with simple obesity.
- Published
- 2022
- Full Text
- View/download PDF
8. Non-immune diabetes mellitus in children due to heterozygous mutations in the glucokinase gene (GCK-MODY): data of 144 patients
- Author
-
E. A. Sechko, T. L. Kuraeva, L. I. Zilberman, D. N. Laptev, O. B. Bezlepkina, and V. A. Peterkova
- Subjects
gck gene ,monogenic diabetes mellitus ,mody ,hyperglycemia in children ,diabetes mellitus in children and adolescents ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Monogenic diabetes mellitus (MDM) is a rare form of diabetes mellitus (DM) which caused by one or more mutations in one of the genes that cause pancreatic β-cell dysfunction. Despite the sufficient knowledge of the most common subtypes of MODY, cases of MDM are undiagnosed and classified as type 1 diabetes mellitus and type 2 diabetes mellitus.AIM: To study the clinical, laboratory characteristics, as well as age-related features of GCK-MODY in children.MATERIALS AND METHODS: The studied population is patients with GCK-MODY under the age of 18 years. The diagnosis was confirmed by genetic test, a heterozygous mutation was identificated in the GCK gene.RESULTS: MODY-GCK was verified in 144 patients (131 probands and 13 siblings) under the age of 18 years. Missense mutations were detected in 80.2% (n=105). Mutation was detected in one case in 59.6%. The most common missense mutations were p.G261R (n=7) and p.G258C (n=6). The age of diagnosis of carbohydrate metabolism disorders was 7.6 years [4.0; 11.2]. In 72.2% carbohydrate metabolism disorders were diagnosed accidentally, in 16.7% the examination was provided due to a family history of diabetes, 11.1% had clinical symptoms of diabetes. Fasting glycemia at diagnosis was 6.8 mmol / l [6.4; 7.3], HbA1c — 6.4% [6.1; 6.7]. At examination, the level of fasting glycemia corresponded to normal values in 16.4% of patients, impaired fasting glycemia — in 57.8%, diabetic — in 25.8%. In 62.3% of patients was impaired glucose tolerance, in 18.9% — to diabetic values, and in 11.7% of patients — to a normal level at 120 minutes during the oral glucose tolerance test. A moderate positive correlation was found between the age of examination and the levels of fasting glycemia (r=0.347, p
- Published
- 2022
- Full Text
- View/download PDF
9. C-peptide levels and the prevalence of islets autoantibodies in children with type 1 diabetes mellitus with different duration of the disease
- Author
-
E. M. Romanenkova, I. A. Eremina, E. V. Titovich, E. A. Sechko, L. V. Nikankina, V. A. Peterkova, O. B. Bezlepkina, and D. N. Laptev
- Subjects
type 1 diabetes ,c-peptide ,autoantibodies ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Type 1 diabetes mellitus (T1DM) is characterized by the development of absolute insulin deficiency. In some patients residual insulin secretion may persist for a long time. C-peptide is a widely used to measure the pancreatic beta cells function, in clinical practice and in research studies.AIM: To assess C-peptide levels and presence of islets autoantibodies (Ab) in children with different duration of T1DM and to identify factors associated with the preserved secretion.MATERIALS AND METHODS: Single-center cross-sectional study including data from 703 cases of children with T1DM, examined in the Endocrinology Research Center in 2016-2020, who was underwent a study of C-peptide levels and was positive for one or more islets antibodies (ZnT8, IA-2, GAD, ICA, IAA). There were 3 groups of patients: 1st — T1DM duration 5 years.RESULTS: The median of the fasting C-peptide level in the 1st group was 0.6 ng/ml [0.27; 1.09]; in the 2nd group — 0.2 ng/ml [0.01; 0.8]; in the 3rd group — 0.01 ng/ml [0.01; 0.037]. The preserved secretion of C-peptide (> 0.6 ng/ml) was determined in 51.4% in the 1st group, in 31.4% — in the 2nd group and in 11.4% in the 3rd group. In patients with obesity during the first year from the T1DM diagnosis C-peptide levels above 1.1 ng/ml was determined significantly more often (65.2%), as well as at the period of 1 to 5 years of the disease (35.7%), compared with children with normal BMI (18.5% and 14.5%, respectively) or overweight (15.7% and 19%, respectively), p
- Published
- 2022
- Full Text
- View/download PDF
10. MODY caused by a mutation in the insulin gene
- Author
-
E. A. Sechko, T. L. Kuraeva, E. A. Andrianova, L. I. Zilberman, A. O. Emelyanov, D. N. Laptev, and O. B. Bezlepkina
- Subjects
gene ins ,monogenic diabetes mellitus ,mody ,diabetes mellitus in children and adolescents ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
MODY10 is a rare subtype of MODY diabetes, which caused by heterozygous mutations in the insulin gene INS. There are single descriptions of families with MODY-INS or MODY10 in the literature, its clinical course is not well understood. We present a case of MODY10 in a boy with a history of diabetes mellitus (DM) in three generations (father and paternal grandmother). Proband was diagnosed with diabetes mellitus at the age of 7 years. The glycaemia at the onset of the diabetes was 10.2 mmol/l, HbA1c — 7.6%, islet cell autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase antibodies (GADA) and islet tyrosine phosphatase 2 (IA2) antibodies (IA2) were not detected. According to the results of the oral glucose tolerance test, fasting blood glucose was 6.5 mmol/l, in 120 minutes 10.3 mmol/l, which corresponded to the diagnosis of impaired glucose tolerance. Diet with restriction of easily digestible carbohydrates was recommended, than gliclazide was added to the therapy, which the proband received for 3 years. At the age of 10, a deterioration in the parameters of carbohydrate metabolism was noted, which insulin therapy was added. Examination at the age of 12 revealed a decrease in C-peptide secretion. The child’s father has a similar phenotype — slowly progressive disorders of carbohydrate metabolism from 6 years old, from 10 years old — insulin therapy. A genetic test was provided, in the child and his father was detected a previously undescribed heterozygous mutation in the INS p.C31W. Thus, in our clinical case, MODY10 was characterized by a milder course than T1DM, but eventually leading to the development of insulin demand, which distinguishes it from the most common forms of MODY. Currently, there is no specific therapy, and the detection of a mutation in the INS gene does not affect therapeutic tactics, however, a correct genetic diagnosis makes it possible to predict the course of diabetes and provide genetic counseling to the family.
- Published
- 2022
- Full Text
- View/download PDF
11. The use of Flash glucose monitoring in children with type 1 diabetes mellitus in real clinical practice
- Author
-
D. N. Laptev, A. O. Emelyanov, E. A. Andrianova, L. I. Zilberman, I. A. Eremina, G. N. Svetlova, E. V. Titovich, O. B. Bezlepkina, and V. A. Peterkova
- Subjects
type 1 diabetes mellitus in children and adolescents ,t1d ,cgm ,continuous glucose monitoring ,fgm ,flash glucose monitoring ,smbg ,self monitoring of blood glucose ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: In 2018, a Frestyle Libre flash glucose monitoring system (FGM) appeared in Russia and became a potential alternative to the traditional CGM. Studies carried out to date have shown the advantages of FGM over SMBG, but only a few of them relate to real clinical practice, especially in children with type 1 diabetes.OBJECTIVE: To evaluate the efficacy of FGM in children with T1DM in relation to glycemic control indicators, the occurrence of severe hypoglycemia and diabetic ketoacidosis, as well as the satisfaction of patients and their parents with the use of FGM.MATERIALS AND METHODS: Single-center, prospective, observational cohort study. Children 4–18 years old with T1DM and HbA1c level less than 10.0% were invited to participate in the study on intensified insulin therapy (by MDI or CSII). The duration of the patient’s participation in the study was 6 months. At baseline and every 3 months thereafter, face-to-face consultations were conducted with an assessment of the general condition, HbA1c study, an assessment of glycemic indicators, progress in relation to glycemic control targets and correction of the therapy. A total of 228 patients (110 boys and 118 girls) who met the inclusion criteria were included in the study. The median age was 11.2 (8.6–14.7) years, the duration of type 1 diabetes was 3.8 (2–7.1), 136 patients received insulin therapy by CSII for 1.3 (0.8–2.6) years.RESULTS: In the general group of patients, 3 and 6 months after the start of FGM use, the HbA1c values decreased statistically significantly by 0.2%. In addition, the number of children with HbA1c
- Published
- 2022
- Full Text
- View/download PDF
12. Carbohydrate metabolism in children after complex treatment of medulloblastoma
- Author
-
A. L. Kalinin, N. A. Strebkova, O. G. Zheludkova, M. A. Kareva, N. A. Mazerkina, and O. B. Bezlepkina
- Subjects
medulloblastoma ,ogtt ,disorders of carbohydrate metabolism ,insulin resistance ,impaired glucose tolerance ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
BACKGROUND: Disorders of carbohydrate metabolism are frequent complications after complex treatment of cancer. Early detection of these disorders allows to modify lifestyle, if necessary, apply drug therapy and correct the identified changes in time, which will subsequently lead to a decrease in cardiovascular risks, an improvement in the quality and an increase in the life expectancy of this group of patients.AIM: To identify the frequency of occurrence and determine the optimal methods for early diagnosis of carbohydrate metabolism disorders in children after complex treatment of medulloblastoma.MATERIALS AND METHODS: 97 patients (64 boys) were examined after complex treatment of medulloblastoma (surgical treatment, craniospinal radiation therapy [CSI], chemotherapy). The median age at the time of the survey was 11.2 (5.29 -17.9) years. The average follow-up period after the end of all types of treatment is 4.7 (0.59 - 11.94) years. At the time of examination, all patients were compensated for hypothyroidism and hypocorticism (if any), and no one was on growth hormone therapy. All patients underwent a standard oral glucose tolerance test (OGTT) and determination of the level of glycated hemoglobin (HbA1c).RESULTS: None of the patients had a basal glycemic level higher than 5.5 mmol / L. Impaired glucose tolerance ( glycemia at the 120th minute ≥7.8 mmol / L
- Published
- 2022
- Full Text
- View/download PDF
13. Remote monitoring of adolescents with type 1 diabetes mellitus using a mobile application
- Author
-
D. N. Laptev, I. A. Eremina, A. V. Karpushkina, E. E. Petryaykina, O. B. Bezlepkina, and V. A. Peterkova
- Subjects
type 1 diabetes mellitus ,adolescents ,remote monitoring ,mobile application ,telemedicine ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Background: The prevalence of type 1 diabetes mellitus (T1DM) in childhood is increasing every year. Adolescence is the most challenging age for achieving optimal metabolic control of T1DM. Telemedicine has already been shown to be effective in children with the condition, but there are not enough studies in adolescents. The use of mobile apps may be associated with better glycemic control in patients with type 1 diabetes.Aims: To assess the effectiveness and safety of a model of medical care for adolescents with type 1 diabetes using remote counseling and a mobile application.Materials and methods: Were included adolescents aged ≥14 and 18 years with a T1DM duration> 3 months, a glycated hemoglobin level (HbA1c)> 7%. The duration of the study was 26 weeks. There were 3 face-to-face and at least 4 remote visits using a mobile application. All patients underwent standard examination and anthropometry, study of HbA1c, registration and analysis of indicators, assessment and correction of the treatment. The quality of life of adolescents was assessed at baseline and at the end of the study. Adolescents and physicians were interviewed about program evaluation.Results: 56 patients were included, 7 adolescents withdrew. HbA1c significantly decreased by the 12th week of the study (–0.3%; p = 0.005), by the end of the study the change in HbA1c was –0.5% (p
- Published
- 2022
- Full Text
- View/download PDF
14. Gonadotropin-dependent precocious puberty: genetic and clinical characteristics
- Author
-
D. A. Khabibullina, A. A. Kolodkina, T. V. Vizerov, N. A. Zubkova, and O. B. Bezlepkina
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
BACKGROUND: In 90% cases of girls and 25–60% cases of boys the cause of gonadotropin-dependent precocious puberty (PP) is unclear. Up to 25–27.5% of gonadotropin-dependent PP cases are monogenic and suggest autosomal-dominant inheritance with incomplete sex-dependent penetrance. To date, mutations in genes KISS1, KISS1R, MKRN3, DLK1 have been described as causal variants leading to precocious hypothalamic-pituitary axis activation in childhood. Genetic testing in patients with hereditary forms of PP can expand our knowledge of underlying molecular mechanisms of the disease and it is also necessary for genetic counselling.AIM: To study clinical features and genetic characteristics of patients with idiopathic gonadotropin-dependent precocious puberty.MATERIALS AND METHODS: A group of patients with idiopathic gonadotropin-dependent precocious puberty and positive family history (early or precocious puberty) was examined. Laboratory and instrumental diagnostic tests, full-exome sequencing (NGS, next-generation sequencing) were provided for all patients.RESULTS: The study included 30 patients (29 girls, 1 boy) with idiopathic gonadotropin-dependent precocious puberty. The median of patients age at the time of the examination was 7,2 years [6,5; 7,7]. Positive family history presented in all cases: in 40% of patients on father’s side, in 37% — on mother’s side, in 23% of patients PP was diagnosed in siblings. The fullexome sequencing was conducted to 21 patients: in 61,9% of cases (95% CI [40;79]) nucleotide variants were identified in genes, associated with gonadotropin-dependent precocious puberty. MKRN3 gene defect was detected in most cases (77% cases (95% CI [49; 92]), which consistent with international data on its highest prevalence in the monogenic forms of PP. In 23% of cases (95% CI [7; 50]) nucleotide variants were identified in other candidate genes associated with neuroontogenesis and neuroendocrine regulation mechanisms of hypothalamic-pituitary axis.CONCLUSION: Our study confirms that detailed family history data in children with PP provides a rational approach to molecular-genetic testing. Data of inheritance pattern and clinical manifestations will simplify the diagnosis of hereditary forms of disease and enhance genetic counselling of families, followed by timely examination and administration of pathogenetic therapy.
- Published
- 2023
- Full Text
- View/download PDF
15. Olfactory function and olfactory bulbs in patients with Kallmann syndrome
- Author
-
K. D. Kokoreva, I. S. Chugunov, V. P. Vladimirova, T. E. Ivannikova, V. P. Bogdanov, and O. B. Bezlepkina
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
BACKGROUND: The majority of Kallmann patients have anosmia or hyposmia. This is how the disease is diagnosed. Some of them don’t have such complaints but olfactory dysfunction is diagnosed via olfactometry. Nowadays there is the lack of information about correlation between olfactometry results and subjective complaints. Correlation between olfactory bulbs size and olfactory dysfunction has been little studied.AIM: To explore olfactory bulb size and olfactory function in patients with congenital isolated hypogonadotropic hypogonadism. To correlate olfactory bulb sizes and smell test scores.MATERIALS AND METHODS: Single-centre comparative study. 34 patients were included. The main group consisted of 19 patients with hypogonadotropic (15 –with Kallmann syndrome, 4 — with normosmic hypogonadism). Olfactory bulbs MRI were provided to all the patients, olfactory test (Sniffin’ Sticks Test) and molecular-genetic studies were provided in all patients with hypogonadism. Control group consisted of 15 patients who were provided with orbits MRI. Olfactory bulbs were evaluated additionally in them.RESULTS: Normal size of olfactory bulbs were only in 1 patient with hypogonadism. Olfactory bulbs height and width were significantly smaller in patients with hypogonadism in comparison with control group (pCONCLUSION: Olfactometry was able to diagnose olfactory dysfunction in 78.5% (i.e. in 15 out of 19 patients with congenital isolated hypogonadotropic hypogonadism. However, anosmia complaints had only 11 out of 19 patients. It is the first results of olfactory bulb sizes in patients with hypogonadotropic hypogonadism in Russia. Uni — or bilateral hypoor aplasia were diagnosed in 94.7% patients with hypogonadism regardless of olfactory dysfunction. Bilateral olfactory bulbs hypoplasia were the most common MRI-finding (36.8%). Unilateral hypoor aplasia was diagnosed in 31.6% patients.
- Published
- 2023
- Full Text
- View/download PDF
16. Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism
- Author
-
K. D. Kokoreva, I. S. Chugunov, M. A. Kareva, and O. B. Bezlepkina
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
BACKGROUND: Gonadotropin therapy in boys with congenital isolated hypogonadotropic hypogonadism helps to increase testes volume and induce spermatogenesis in comparison with testosterone therapy. However, difficulties with dose titration, partial therapy success, absence of generally accepted regimen protocols don’t allow to use this therapy in order to induce puberty in adolescents with Kallmann syndrome or normosmic hypogonadotropic hypogonadism.AIM: To assess the effectiveness of combination hormonal replacement therapy via human chorionic gonadotropin and recombinant follicle stimulation hormone in adolescents with congenital isolated normosmic hypogonadotropic hypogonadism and with Kallmann syndromeMATERIALS AND METHODS: This is an open single-center prospective non-controlled study. Boys with hypogonadotropic hypogonadism were receiving hormonal replacement therapy for 12 months. Initial dose of human chorionic gonadotropin was 500 IU per week. Initial dose of recombinant follicle stimulation hormone was 37.5 IU per week. Doses were doubled in 6 months. Antropometric data, Tanner stage, testes volumes, inhibin B and anti-Mullerian hormone (AMH) levels were evaluated in all the patients before the treatment, after 6 and 12 months of the therapy.RESULTS: 8 boys with hypogonadotropic hypogonadism were included into the study. Median age before therapy initiation was 15.7 years [15.33; 16.41]. In 12 months after the therapy initiation puberty development, testosterone increase from 0.44 [0.34;0.62] to 4.39 [0.88;10.51] nmol/l (p=0.012), AMH decrease from 35.70 [18.00;59.00] to 14.41 [11.60;16.65] ng/ml were noted in all the patients (p=0.017). Testes volumes increase and inhibin B level increase were not statistically significant.CONCLUSION: Gonadotropin therapy is effective in order to puberty initiation in adolescents with congenital hypogonadotropic hypogonadism. In helps to achieve not only androgenization, but also to Sertoli cells maturation.
- Published
- 2023
- Full Text
- View/download PDF
17. Pathogenic TSHR variants in children with thyroid dysgenesis
- Author
-
E. V. Shreder, T. A. Vadina, E. N. Solodovnikova, V. V. Zakharova, M. V. Degtyarev, M. B. Konyukhova, N. V. Sergeeva, and O. B. Bezlepkina
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
BACKGROUND: Loss-of-function mutations in the TSH receptor gene (TSHR) (NP_000360.2) are the potential causes of thyroid dysgenesis in patients with congenital hypothyroidism. Heterozygous variants of the TSHR gene lead to partial resistance to TSH, homozygous and compound heterozygous variants have been shown to cause CH due to thyroid hypoplasia or TSH resistance. Recently more and more articles in this field have appeared in the international literature sources, while local publications are limited. The studies are necessary to understand the etiology, pathogenesis of the disease, to improve the management of these patients.AIM: To assess the frequency of incidence of pathogenic variants of the TSHR gene in children with CH due to thyroid dysgenesis. To study inheritance and phenotypic patterns of CH in families.MATERIALS AND METHODS: In this single-center interventional one-stage non-comparative study a group of CH patients was examined. The patients underwent neck ultrasound and radionuclide imaging. The examination was performed 14 days after hormone replacement therapy suspension or prior to its initiation. The structure of thyroid dysgenesis was estimated, genetic testing for mutations in the TSHR gene was performed using the NGS method.RESULTS: The study included 95 children with primary CH (75 girls; 20 boys). The patients’ median age at the time of examination was 6.2 years [4.5; 8.9], the median level of neonatal TSH was 157.5 mU/l [60.9; 257.2]. Ectopic thyroid was found in 52% of children, aplasia in 36%, hypoplasia and hemiagenesis in 10% and 2%, respectively. In 5.4% of cases (in 5 out of 95 patients), different variants of the TSH gene were detected. Two children had heterozygous p.R450H and p.D487N variants in TSHR gene, two patients was homozygous for the p.S49Afs * 9 variant, one child had compound heterozygous variants (p.A485D and p.R450H). According to ultrasound imaging, all patients had thyroid hypoplasia of varying severity. Three children underwent thyroid scintigraphy, which revealed decreased 99mТc pertechnetate uptake (0.3–0.9%).CONCLUSION: In our study, the incidence of different variants in the TSHR gene in children with CH was 5.3%. Our analysis uncovered two previously undescribed variants. Genetic testing may be able to help with making the diagnosis, patient’s management, and genetic counseling.
- Published
- 2023
- Full Text
- View/download PDF
18. Modern strategies for the treatment of childhood obesity
- Author
-
O. V. Vasyukova, P. L. Okorokov, and O. B. Bezlepkina
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
The prevalence of obesity and related metabolic disorders in children and adolescents in the Russian Federation is steadily increasing, which requires healthcare professionals to search for new methods of treatment and prevention. The treatment of childhood obesity should be based on a comprehensive approach, including diet therapy, increased physical activity, behavioral therapy and psychological support. To increase the effectiveness of the formation of new eating habits and proper eating behavior, as well as to increase the adherence of children and adolescents to treatment, drug therapy of obesity is used, aimed primarily at reducing appetite. Considering the efficacy and safety of glucagon-like peptide 1 analog (Liraglutide) in adolescents, as well as a small number of gastrointestinal side effects, this drug is promising in the complex treatment of childhood obesity. This review presents an analysis of the literature on non-medicated and drug-based methods of treatment of childhood obesity.
- Published
- 2022
- Full Text
- View/download PDF
19. A clinical Case and brief literature review of Icenko-Cushing’s Disease in a pediatric patient with atypical onset of the disease
- Author
-
M. A. Tiulpakov, O. B. Bezlepkina, E. V. Nagaeva, V. N. Azizian, and A. M. Lapshina
- Subjects
Adenoma ,Adult ,Adolescent ,Child, Preschool ,Endocrinology, Diabetes and Metabolism ,Hypertension ,Humans ,Obesity ,Child ,Pituitary ACTH Hypersecretion ,Cushing Syndrome - Abstract
Itsenko–Cushing’s disease is a rare, multisystem disease characterized by the presence of endogenous central hypercortisolism due to an ACTH-secreting brain tumor. The frequency of Itsenko-Cushing’s disease in adulthood is 0.7–2.4 per 1 million population, and only 10% of all cases occur in childhood. The age of onset of the disease in children is on average 12.0–14.8 years. A typical manifestation of the disease in children, along with obesity and arterial hypertension, is a decrease in growth rates. The gold standard for diagnosing central hypercortisolism is MRI of the brain, however, the effectiveness of this method in children is only 50%. The main method of treatment is neurosurgical transnasal transsphenoidal removal of endosellar pituitary adenoma, which makes it possible to achieve remission in more than 65% of cases. This article describes a clinical case of Itsenko–Cushing’s disease in a 6.5-year-old child with obesity, arterial hypertension, atypically «high» stature, average velocity and non-visualizable corticotropinoma. The article presents the stages of diagnostic search, the complexity of differential diagnosis and surgical treatment, the results of follow-up after the treatment and a brief review of the literature.
- Published
- 2022
- Full Text
- View/download PDF
20. Definitive treatment of Graves’ disease in children
- Author
-
T. E. Ivannikova, T. Yu. Shiryaeva, E. V. Nagaeva, M. S. Sheremeta, D. N. Brovin, and O. B. Bezlepkina
- Subjects
Graves Ophthalmopathy ,Iodine Radioisotopes ,Endocrinology, Diabetes and Metabolism ,Humans ,Prospective Studies ,Thyroid Neoplasms ,Child ,Graves Disease ,Retrospective Studies - Abstract
BACKGROUND: Hyperthyreoidism due to Graves’ disease is a rare disorder in pediatric practice. There is 2 treatment options in Graves’ disease: medical treatment and definitive treatment, including surgery and radioactive iodine. Each method has its advantages and disadvantages. If medical therapy is ineffective the choice between radical treatment method is raised: radioactive iodine or total thyroidectomy. In this research we analyze treatment outcomes in pediatric Graves’ disease patients after different radical treatment methods.AIM: Comparative analysis of radical treatment outcomes in pediatric patients with Graves’ disease.MATERIALS AND METHODS: Retrospective and prospective one-center research of 122 patients with Graves’ disease after radical treatment (between 2016 and 2021)RESULTS: The mean age was 13.5±3,5 year at the moment of examination. Patients were divided into 2 groups due to the radical treatments method: 1 group (n=60) were children after surgical treatment, 2 group (n=62) — after radioactive iodine. The mean dose of medical treatment in these groups did not reliably differ (p=0,06), duration of the medical treatment was reliably longer in patients after radioactive iodine (p=0,024). Graves’ orbitopathy was diagnosed in 58 patients (47,5%) and met equally often in both groups, but active stage of Graves’ orbitopathy was diagnosed only in patients from the 1st group. Thyroid size was reliable bigger in patients from the 1st group (p=0,004), and thyroid gland nodes were diagnosed only in patients from 1st group (p=0,0007).CONCLUSION: RI can be considered an effective and safe treatment for GD. The effectiveness of RI depends on the volume of the thyroid gland; according to the results of the constructed ROC curve, the risk of repeated RI is higher with a volume of more than 55 cm3. Also radioactive iodine is undesirable if there is signs of ophatalmopathy due to its possible deterioration. According to the results of the study hypoparathyroidism after surgical treatment was diagnosed in 20%, recurrent laryngeal nerve injury was diagnosed after surgical treatment in 5% of patients. In patients with identified nodular goiter according to the results of ultrasound, surgical treatment is preferable due to the impossibility of excluding thyroid cancer.
- Published
- 2022
- Full Text
- View/download PDF
21. Ectopic thyroid gland: clinical features and diagnostics in children
- Author
-
E. V. Shreder, T. A. Vadina, M. B. Konyukhova, E. V. Nagaeva, T. Y. Shiryaeva, S. M. Zakharova, M. V. Degtyarev, E. O. Vyazmenov, and O. B. Bezlepkina
- Subjects
Neonatal Screening ,Endocrinology, Diabetes and Metabolism ,Thyroid Dysgenesis ,Congenital Hypothyroidism ,Infant, Newborn ,Humans ,Choristoma ,Child ,Radionuclide Imaging ,Tongue Diseases - Abstract
BACKGROUND: The frequency of ectopia of thyroid gland among all types of dysgenesis varies from 30 to 70%, its most common localization is the root of the tongue. Otorhinolaryngologists, oncologists, pediatricians can take lingual ectopia for hypertrophy of the lingual tonsil or fibroma of the tongue root, which leads to unreasonable surgical treatment. Thyroid scintigraphy plays a key role in the diagnosis of ectopia.AIM: To assess the etiological structure of congenital hypothyroidism (CH) and demonstrate the clinical course in patients with ectopic thyroid tissue in the root of the tongue.MATERIALS AND METHODS: A group of patients with CH was examined. All patients underwent neck ultrasound and radionuclide imaging. The examination was carried out against the background of the abolition of hormone replacement therapy for 14 days or before its initiation. Patients with ectopia in the root of the tongue underwent videofibrolaryngoscopy. Some patients underwent a genetic study with using genes panel of a panel of candidate genes responsible for the development of CH using the NGS method. The molecular genetic study was conducted to some patients, next-generation sequencing with the genes panel.RESULTS: The study included 73 patients with primary CH aged from 2 weeks to 17.3 years: 69 children were diagnosed based on the results of neonatal screening, 4 children with thyroid ectopia were first examined older than 6 years. The median age of patients at the time of the examination was 6.9 years [4.8; 10.0]. By data of ultrasound aplasia was diagnosed in 47.9% of patients, one child had hemiagenesis and ectopic thyroid tissue of various localization was detected in 26.0% of children. In 24.7% of children thyroid tissue was found in a typical location. Scintigraphy confirmed thyroid aplasia in 65.7% of children. Examination revealed various variants of ectopically located thyroid tissue in 31 children (42.4%): thyroid ectopia in the root of the tongue in 25 children (80.6%), ectopia in the sublingual region in 5 children (16.2%), double ectopia was detected in 1 child. The median level of TSH in newborns with ectopic thyroid gland was 124 IU/ml and was significantly lower than in children with aplasia — 219 IU/ml, pCONCLUSION: Combination of two methods is the best diagnostic approach to determine the etiology of CH — ultrasound and scintigraphy studies compensates deficiencies of each other. Our study demonstrates the importance of scintigraphy in children with CH and patients with the formation of the root of the tongue and the anterior surface of the neck in order to avoid unnecessary removal of the thyroid gland. In case of confirmation of thyroid ectopia in the root of the tongue and in the absence of symptoms of obstruction or bleeding, it is recommended to refer the patient to an endocrinologist for conservative treatment.
- Published
- 2022
- Full Text
- View/download PDF
22. Clinical guideline of «congenital hypothyroidism»
- Author
-
V. A. Peterkova, O. B. Bezlepkina, T. U. Shiryaeva, T. A. Vadina, E. V. Nagaeva, O. A. Chikulaeva, E. V. Shreder, M. B. Konuhova, N. A. Makretskaya, E. A. Shestopalova, and V. B. Mitkina
- Subjects
Endocrinology ,Evidence-Based Medicine ,Physicians ,Endocrinology, Diabetes and Metabolism ,Congenital Hypothyroidism ,Humans ,Pediatricians ,Child - Abstract
Congenital hypothyroidism is an important issue of pediatric endocrinology at which timely diagnosis and treatment can prevent the development of severe cases of the disease. The developed clinical guidelines are a working tool for a practicing physician. The target audience is pediatric endocrinologists and pediatricians. They briefly and logically set out the main definition of the disease, epidemiology, classification, methods of diagnosis and treatment, based on the principles of evidence-based medicine.
- Published
- 2022
- Full Text
- View/download PDF
23. Clinical guidelines «Thyroiditis in children»
- Author
-
V. A. Peterkova, O. B. Bezlepkina, E. V. Nagaeva, T. Y. Shiryaeva, O. A. Chikulaeva, T. A. Vadina, E. V. Shreder, T. E. Taranushenko, E. E. Petryaykina, O. A. Malievskiy, A. V. Kiyaev, I. B. Kostrova, E. B. Bashnina, E. G. Mikhailova, Ya. V. Girsh, E. B. Khramova, I. L. Alimova, L. N. Samsonova, and N. V. Bolotova
- Subjects
General Medicine - Abstract
The thyroiditis in children are urgent problem of pediatric endocrinology due to the widespread occurrence and characterized by clinical and pathogenetic heterogeneity. The developed clinical guidelines are the main working tool of the practitioner. They briefly and structurally present the main information about the epidemiology and modern classification of thyroiditis, methods of their diagnosis and treatment based on the principles of evidence-based medicine.
- Published
- 2021
- Full Text
- View/download PDF
24. Myokines and adipomyokines: inflammatory mediators or unique molecules of targeted therapy for obesity?
- Author
-
Yu. V. Kasyanova, O. V. Vasyukova, P. L. Okorokov, and O. B. Bezlepkina
- Subjects
Muscle tissue ,medicine.medical_specialty ,FGF21 ,biology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Adipose tissue ,Myostatin ,Muscle hypertrophy ,Endocrinology ,medicine.anatomical_structure ,Adipose Tissue ,Internal medicine ,Myokine ,medicine ,biology.protein ,Humans ,Myocyte ,Obesity ,Inflammation Mediators ,Child ,Muscle, Skeletal ,business ,Exercise ,Thermogenesis - Abstract
Skeletal muscles make up about 25% of the total mass in children and more than 40% in adults. Studies of the last twenty years have shown that along with the main functions, muscle tissue has hormonal activity. It was found that myocytes are able to release signaling molecules-myokines. They act auto-and paracrine within the muscle, and at a high level-through the systemic circulation, carrying out interactions between skeletal muscles and various organs and tissues, such as the liver, bone and adipose tissue, the brain. It is proved that the key factor in the expression of myokines is physical activity, and their level largely depends on physical fitness, the amount of skeletal muscle mass and its composition (the ratio of fast and slow fibers), on the intensity and duration of physical activity. Myokines have a wide range of physiological effects: myostatin suppresses the growth and differentiation of muscle tissue, and decorin, acting as its antagonist, promotes muscle hypertrophy. Interleukin 6 provides an energy substrate for contracting muscle fibers, fibroblast growth factor 21 activates the mechanisms of energy production during fasting and improves tissue sensitivity to insulin; irisin stimulates thermogenesis, glucose uptake by myocytes, and also contributes to an increase in bone mineral density. The study of myokines is one of the key links in understanding the mechanisms underlying obesity and metabolic complications, the consequences of a sedentary lifestyle, as well as the implementation of the action of physical activity. Taking into account the physiological effects of myokines in the body, in the future they can become therapeutic targets for the treatment of these conditions.
- Published
- 2021
- Full Text
- View/download PDF
25. Nodular toxic goiter in children: clinical features, morphological variants
- Author
-
T. E. Ivannikova, O. B. Bezlepkina, N. A. Zubkova, M. V. Degtyarev, F. M. Abdulhabirova, and A. U. Abrosimov
- Subjects
endocrine system ,medicine.medical_specialty ,Goiter ,Adolescent ,endocrine system diseases ,Adenoma ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Hyperthyroidism ,03 medical and health sciences ,0302 clinical medicine ,Follicular phase ,medicine ,Humans ,Toxic goiter ,Child ,Retrospective Studies ,Subclinical infection ,business.industry ,Thyroid ,Toxic nodular goiter ,medicine.disease ,Dermatology ,Thyrotoxicosis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Thyroidectomy ,business ,Goiter, Nodular ,Rare disease - Abstract
BACKGROUND: Toxic nodular goiter (TNG) is a rare disease in which the cause of hyperthyroidism is the presence of a node or nodes that autonomously secrete thyroid hormones. With children and adolescents this condition is extremely rare — in 5–7.5% of all cases of nodular goiter. Therapy of toxic nodular goiter is aimed at relieving the symptoms of hyperthyroidism taking into account the malignant potential of the nodular formation. In the available literature, there are no data on the clinical course, comparative results of cytological and histological data in patients with toxic nodular goiter, which debuted in their childhood.AIM: Analysis of the features of the clinical course, comparison of the results of cytological and histological studies of toxic nodular goiter in children and adolescents.MATERIALS AND METHODS: A retrospective, single-center study of 21 patients with single-nodular toxic goiter, hospitalized at the Endocrinology Research Centre in the period from January 2016 to December 2019.RESULTS: The mean age at the time of the survey was 13.9 years. Thirteen patients (65%) had manifest thyrotoxicosis, and seven (35%) had subclinical hyperthyroidism. More than half of children — 57.1% (n = 12) did not receive thyreostatic therapy. The cytological picture in 11 patients (61.1%) corresponded to benign changes (nodular colloid goiter or adenomatous goiter) — Bethesda II, in 4 patients — follicular tumor — Bethesda IV, in 4 children the study was not informative. 19 patients (90.5%) underwent surgical treatment (hemithyroidectomy). According to the results of histological examination, follicular adenoma was found in 44.4% of children with nodular toxic goiter with benign results of TAB (Bethesda II) and was found in 50% with revealing follicular neoplasia (Bethesda IV).CONCLUSION: For the first time in the Russian Federation was carried out a comparative analysis of the characteristics of cytological and histological studies in children with toxic nodular goiter. It is significant that only in 10.5% (n=2) cytological and morphological results were consistent. The choice of radical treatment tactics should take into account the high frequency of mismatches between histological and morphological studies.
- Published
- 2021
- Full Text
- View/download PDF
26. Clinical practice guidelines 'Management of iodine deficiency disorders'
- Author
-
Valentina Alexandrovna Peterkova, T. V. Soldatova, A. A. Rybakova, T A Vadina, F M Abdulkhabirova, O B Bezlepkina, Nadezhda M. Platonova, Elena Nagaeva, D N Brovin, Ekaterina Troshina, Galina A. Melnichenko, Tatiana Yu. Shiryaeva, and Larisa Nikankina
- Subjects
Adult ,endocrine system ,Pediatrics ,medicine.medical_specialty ,Goiter ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Thyroglobulin ,03 medical and health sciences ,0302 clinical medicine ,Multinodular goiter ,Epidemiology ,medicine ,Humans ,Child ,business.industry ,Euthyroid Goiter ,Thyroid ,Infant, Newborn ,medicine.disease ,Iodine deficiency ,Clinical Practice ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business ,Biomarkers ,Goiter, Nodular ,Iodine - Abstract
Iodine deficiency disorders is a sweeping term that includes structural and functional impairment of the thyroid gland.These clinical guidelines include algorithms for the diagnosis and treatment of euthyroid goiter and nodular/ multinodular goiter in adults and children. In addition, these clinical guidelines contain information on methods for an adequate epidemiological assessment of iodine deficiency disorders using such markers as the percentage of goiter in schoolchildren, the median urinary iodine concentration, the level of neonatal TSH, the median thyroglobulin in children and adults. As well from these clinical guidelines, you can get to know the main methods and groups of epidemiological studies of iodine deficiency disorders.
- Published
- 2021
- Full Text
- View/download PDF
27. [Myokines in obese adolescents with aerobic exercise]
- Author
-
Yu. V. Kasyanova, O. V. Vasyukova, P. L. Okorokov, Z. T. Zuraeva, and O. B. Bezlepkina
- Subjects
Male ,Pediatric Obesity ,Adolescent ,Interleukin-6 ,Endocrinology, Diabetes and Metabolism ,Humans ,Female ,Decorin ,Myostatin ,Child ,Exercise ,Fibronectins - Abstract
BACKGROUND: Myokines are synthesized by myocytes and released into the bloodstream in response to muscle fiber contraction. They have a positive effect on carbohydrate and lipid metabolism, muscle mass growth, osteogenesis, increase tissue sensitivity to insulin, counteract inflammation of adipose tissue. The study of their secretion in response to physical activity (FA) can help to personalize the therapy of obesity.AIM: to study the features of the secretion of myokines in children with constitutionally exogenous obesity during physical activity of different duration and intensity and to evaluate their relationship with the parameters of the body composition.MATERIALS AND METHODS: 26 children (10 boys and 16 girls) were included in the study 15 [13; 16] years old, SDS BMI: +2.91 [2.24; 3.29], with sexual development according to Tanner 4–5. Two groups of 13 people were formed by random distribution. Group I performed FA (walking on a treadmill under the control of heart rate) of different duration: 30 and 60 minutes at the same intensity (less than 3 metabolic equivalents (MET)). Group II — FA of different intensity: low — less than 3 METH and moderate — 3–6 METH with the same duration of 45 minutes. Commercial kits for enzyme immunoassay were used to determine the level of myokines. The assessment of the compositional composition of the body was carried out by bioimpedance analysis (analyzer In Body 770, South Korea) in the morning, on an empty stomach. Statistical processing was carried out using STATISTICA v.12.0 (StatSoftInc., USA). The results are presented in the form of median (Me) and quartiles (Q1; Q3) corresponding to 25 and 75 percentiles. The critical significance level (p) was assumed to be RESULTS: moderate intensity FA leads to a maximum increase in the level of myokines: interleukin-6 (IL-6) by 215.7% and decorin by 34.3%, a decrease in the level of irisin by 16.5%. An hour-long low-intensity workout leads to a moderate increase in the level of IL-6 by 80.5%, to a decrease in the level of irisin by 31.1%. Myostatin increases equally both after 60-minute FA and after moderate intensity FA by 30.9% and 31.8%, respectively. Short low-intensity FA (lasting 30 minutes) it is not accompanied by a significant increase in the expression of myokines. The relationship between the amount of muscle (r=0.65), lean (r=0.62), fat-free mass (r=0.64) and the level of decorin after FA was noted. There was no statistically significant relationship between the parameters of the body composition and the levels of IL-6, myostatin, and irisin. There were no gender differences in both basal and stimulated myokine secretion.CONCLUSION: Moderate intensity FA and low intensity 60-minute FA are most effective for obese children. A 30-minute low-intensity FN is insufficient to increase the secretion of myokines by skeletal muscles.
- Published
- 2022
28. [Donohue syndrome and use of continuous subcutaneous IGF1 pump therapy]
- Author
-
M. A. Melikyan, T. E. Ivannikova, N. V. Milovanova, A. A. Kolodkina, O. B. Bezlepkina, and N. G. Mokryshevа
- Subjects
Male ,Donohue Syndrome ,Endocrinology, Diabetes and Metabolism ,Humans ,Insulin ,Insulin-Like Growth Factor I ,Insulin Resistance ,Receptor, Insulin - Abstract
Donohue syndrome (DS), also called Leprechaunism, is the most severe form of insulin resistance associated with biallelic mutations in INSR gene (OMIM: 147670). The approximate incidence of this syndrome is 1 per 1000000 births. Patients are present with typical clinical features such as intrauterine growth retardation, facial dysmorphism, severe metabolic disturbances, hepatomegaly and hypertrophic cardiomyopathy. Most DS patients die within the first two years of life due to respiratory infections, severe hypoglycemia or progressive cardiomyopathy. Treatment options are limited and no specific therapy exist for DS. Given the similarities between insulin and insulin-like growth factor 1 (IGF-1) receptors, recombinant human IGF-1 (rhIGF-1) has been used to treat severe insulin resistance including DS.We report the case of a male patient with genetically confirmed Donohue syndrome, successfully treated with continuous subcutaneous IGF1 infusion via insulin pump. We observed improvement of glycemic control, liver function and cardiac hypertrophy regression following 15-month IGF1 therapy.
- Published
- 2022
29. [Evaluation of FreeStyle Libre in pediatric t1dm: improved glycemic control, reduction in diabetic ketoacidosis and severe hypoglycemia]
- Author
-
D. N. Laptev, O. B. Bezlepkina, E. S. Demina, O. A. Malievskiy, I. L. Nikitina, I. G. Samoilova, and V. A. Peterkova
- Subjects
Blood Glucose ,Glycated Hemoglobin ,Male ,Endocrinology, Diabetes and Metabolism ,Blood Glucose Self-Monitoring ,Glycemic Control ,Hypoglycemia ,Diabetic Ketoacidosis ,Diabetes Mellitus, Type 1 ,Humans ,Hypoglycemic Agents ,Female ,Prospective Studies ,Child - Abstract
BACKGROUND: Self-monitoring of blood glucose (SMBG) with glucometers provides only a snapshot of the glycemic profile and is accompanied by significant psychological discomfort and pain, especially in children. Flash Glucose Monitoring System — FreeStyle Libre (FSL) overcomes many of the barriers associated with glucose measurement and improves metabolic control.AIM: To evaluate the efficacy of FSL in children with type 1 diabetes mellitus (T1DM) in terms of glycemic control, episodes of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA).MATERIALS AND METHODS. A multicenter, prospective, observational study in real clinical practice was carried out. A total of 469 subjects (258 boys and 211 girls) aged 4–18 were included in the study. The median age was 11.3 (8.4–14.6) years, duration of T1DM — 4.2 (2.1–7.1) years. After FSL start, patient was followed up for 6 months.RESULTS: After 3 and 6 months of FSL use, HbA1c significantly decreased from 7.4% to 7.1% and 7.2%, respectively (pCONCLUSION: The Study demonstrated a significant improvement in metabolic control in children with T1DM 6 months after FSL start: decrease in HbA1c, accompanied by reduction in incidence of DKA and SH.
- Published
- 2022
30. Course of Cushing's disease and treatment outcomes in correlation with pituitary MRI in children
- Author
-
E. A. Yanar, N. V. Makazan, M. A. Kareva, A. V. Vorontsov, V. P. Vladimirova, O. B. Bezlepkina, and V. A. Peterkova
- Subjects
Adenoma ,Treatment Outcome ,Endocrinology, Diabetes and Metabolism ,Growth Hormone ,Humans ,Pituitary Neoplasms ,Child ,Pituitary ACTH Hypersecretion ,Magnetic Resonance Imaging ,Diabetes Insipidus ,Hypopituitarism ,Retrospective Studies - Abstract
BACKGROUND: Cushing’s disease (CD) is a rare disorder of a persistent cortisol excess caused by ACTH-secreting pituitary tumor (corticotropinoma). Transsphenoidal surgery (TSS) is a treatment of choice for СD, which effectiveness range is from 70 to 90%. Recurrence rate after successful treatment is about 25%. If surgical treatment is unsuccessful or recurrence appear, radiation treatment is the next therapeutic option, which effectiveness range is also 90%, but the hypopituitarism rate as side effect of treatment is higher. Preoperative predictors of remission and recurrence are still unexplored what leads to further investigations.AIM: Analysis of remission and recurrence rates of pediatric CD after successful treatment according to preoperative MRI and therapeutic option.MATERIALS AND METHODS: We conducted a retrospective analysis of 90 pediatric patients with CD who were observed between 1992 and 2020 at the Endocrinology Research Centre.RESULTS: The most common clinical symptoms of CD were weight gain [94%] and growth retardation [72%]. Pituitary tumor was detected on radiological imaging in 53/90 patients [59%], there were no signs of visible adenoma in 37/90 of patients [41%]. 63 of 90 patients underwent TSS (70%), 27 patients underwent radiosurgery (30%). Remission rate after TSS was 71% [45/63], after radiosurgery — 85% [23/27]. There were no significant differences in remission rates after radical treatment according to preoperative MRI results (P=0.21 after TSS and P=0.87 after radiosurgery, х2 analysis). Recurrence after successful treatment was diagnosed in 10 patients. There were no significant differences in time to recurrence according to preoperative MRI results (P=0.055, х2 analysis). Time to recurrence was statistically different after TSS compared to radiosurgery (P=0.007, Kaplan–Meier analysis) and in the group with developed adrenal insufficiency in the early postoperative period (P=0.04, Kaplan–Meier analysis). Analysis of side effect of treatment showed that the frequency of growth hormone and gonadotrophin deficiency was statistically higher after radiosurgery (р< 0.01, Kruskel–Wallis ANOVA test). Diabetes insipidus was diagnosed only after TSS.CONCLUSION: Results of our study didn`t allow to use MRI-results as predictor of effectiveness treatment in pediatric CD. Therapeutic option has an impact on time to recurrence, not on recurrence rates. The frequency of growth hormone and gonadotrophin deficiency was statistically higher after radiosurgery compared to TSS. Further studies are needed to identify predictors of remission and recurrence in CD.
- Published
- 2021
31. Early correction of hypospadias in girl with a disorder of sex development. clinical case
- Author
-
A. V. Anikiev, D N Brovan, A. B. Okulov, O B Bezlepkina, E. A. Volodko, and N. Yu. Kalinchenko
- Subjects
medicine.medical_specialty ,Genitourinary system ,business.industry ,Feminization (biology) ,Urinary system ,media_common.quotation_subject ,General Medicine ,Hydrocolpos ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Labia minora ,Hypospadias ,medicine ,Congenital adrenal hyperplasia ,Girl ,business ,media_common - Abstract
The presented clinical case of a girl with a salt-wasting form of congenital adrenal hyperplasia in combination with chronic recurrent infection and lower urinary tract dysfunction demonstrates the need to change conventional two-staged approach to surgical feminization in favor of a one-stage intervention in order to prevent a progression of genitourinary complications. After controlling for the underlying condition, the one-stage feminization was performed, including modified tightening introitoplasty using a Passerini-Glazel flap and a correction of hypertrophic clitoris and labia minora. Good short- and long-term results were achieved.
- Published
- 2019
- Full Text
- View/download PDF
32. [Clinical guidelines «Obesity in children»]
- Author
-
N. V. Bolotova, Valentina Alexandrovna Peterkova, E. G. Mikhailova, O. A. Malievskiy, E. E. Petryaykina, P. L. Okorokov, Elena B. Khramova, Ya. V. Girsh, O. V. Vasyukova, E. A. Bogova, I. B. Kostrova, O. B. Bezlepkina, T. E. Taranushenko, and A. V. Kiyaev
- Subjects
Adult ,medicine.medical_specialty ,Pediatric Obesity ,Evidence-Based Medicine ,Pediatric endocrinology ,business.industry ,Endocrinology, Diabetes and Metabolism ,medicine.disease ,Obesity ,Childhood obesity ,Endocrinology ,Classification of obesity ,Epidemiology ,medicine ,Humans ,business ,Intensive care medicine ,Child - Abstract
Childhood obesity is an urgent problem of pediatric endocrinology due to the widespread occurrence, the development of metabolic complications and their steady tracking into adulthood. The developed clinical guidelines are the main working tool of the practitioner. They briefly and structurally present the main information about the epidemiology and modern classification of obesity, methods of its diagnosis and treatment based on the principles of evidence-based medicine.
- Published
- 2021
33. [Molecular genetics and phenotypic features of congenital isolated hypogonadotropic hypogonadism]
- Author
-
I S Chugunov, K D Kokoreva, and O B Bezlepkina
- Subjects
Isolated hypogonadotropic hypogonadism ,endocrine system ,Candidate gene ,Pituitary gland ,medicine.medical_specialty ,Kallmann syndrome ,Endocrinology, Diabetes and Metabolism ,Hypogonadism ,Disease ,Kallmann Syndrome ,Biology ,medicine.disease ,Bioinformatics ,Phenotype ,Gonadotropin-Releasing Hormone ,medicine.anatomical_structure ,Hypogonadotropic hypogonadism ,Molecular genetics ,medicine ,Humans ,Molecular Biology - Abstract
Congenital isolated hypogonadotropic hypogonadism includes a group of diseases related to the defects of secretion and action of gonadotropin-releasing hormone (GNRH) and gonadotropins. In a half of cases congenital hypogonadism is associated with an impaired sense of smell. It’s named Kallmann syndrome. Now 40 genes are known to be associated with function of hypothalamus pituitary gland and gonads. Phenotypic features of hypogonadism and therapy effectiveness are related to different molecular defects. However clinical signs may vary even within the same family with the same molecular genetic defect. Genotype phenotype correlation in patients with congenital malformations prioritizes the search for mutations in candidate genes. There are data of significant contribution of oligogenicity into the phenotype of the disease are presented in the review. Moreover, an issue of current isolated hypogonadotropic hypogonadism definition and classification revision is raised in the review due to hypogonadotropic hypogonadism development while there are mutations in genes not associated with GNRH neurons secretion and function.
- Published
- 2021
34. [Pediatric endocrinological service in the Russian Federation: current state and development prospects]
- Author
-
O. B. Bezlepkina
- Subjects
medicine.medical_specialty ,Financial Management ,Pediatric endocrinology ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,virus diseases ,Beds ,Medical care ,Russia ,State (polity) ,Family medicine ,Service (economics) ,Political science ,medicine ,Normative ,Humans ,Russian federation ,Child ,geographic locations ,media_common - Abstract
The article provides brief data on the prevalence of endocrine diseases in children in the Russian Federation, provides the main normative documents regulating the provision of medical care in the field of «pediatric endocrinology», data on the state of the bed fund (children's endocrinological beds), the number of specialized children's departments in the Russian Federation, the number of children's endocrinologists.
- Published
- 2020
35. The first domestic experience with the use of human growth hormone in adult patients with growth hormone deficiency
- Author
-
V. C. Oganov, O. B. Bezlepkina, A. V. Bakulin, L. V. Murashko, I. I. Dedov, E. B. Koledova, and E. V. Nagaeva
- Subjects
medicine.medical_specialty ,Endocrinology ,Adult patients ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,Human growth hormone ,medicine ,business ,medicine.disease ,Growth hormone deficiency - Abstract
The paper presents the results of treatment in 45 adult patients with somatotropic insufficiency. The study was undertaken to compare the efficiency of treatment of the patients with different doses of the human growth hormone Humatrop and to evaluate its safety. The treatment lasted 6 months. Within the first 3 months, Group 1 patients (n = 24) received Humatrop in a dose of 3.0 pg/kg/day, Group 2 patients (n = 24) had its dose of 6.0 pg/kg/day. Later on the dose was doubled in both groups. The criteria for therapeutic efficiency were changes in the body’s structure (LBM, FM), insulin-like growth factor 1 (IGF-1), and IGF-binding protein-3. In both groups, there was an increase in lean body mass (p < 0.001 in Group 1 and p < 0.018 in Group 2) and a decrease in fatty body mass (p — 0.005 and p < 0.001, respectively) by the end of treatment. The levels of IGF-1 and IGF-binding protein-3 were higher just by the end of the third month of treatment (p < 0.001). There were group differences in all the indices of therapeutic efficiency throughout the treatment period. Side effects were slightly more frequently observed in Group 2 patients. The findings allow Humatrop to be recommended in a dose 3 pg/kg/day within the first 3 months of treatment since the dose is as effective as the larger dose (6 pg/kg/day). Further, the dose of the agent should be changed on an individual basis depending on the levels of IGF-1 and the presence of adverse reactions.
- Published
- 2004
- Full Text
- View/download PDF
36. Secondary hypothyroidism: specific features of diagnosis and treatment
- Author
-
N. P. Goncharov, Valentina Alexandrovna Peterkova, O. B. Bezlepkina, Ye. V. Nagayeva, and G. S. Kolesnikova
- Subjects
endocrine system ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,hormones, hormone substitutes, and hormone antagonists - Abstract
The article is devoted to the secondary hypothyroidism: specific features of diagnosis and treatment
- Published
- 2002
- Full Text
- View/download PDF
37. Intellectual outcome in patients with congenital hypothyroidism
- Author
-
O B Bezlepkina, T A Klimenko, and O A Chikulaeva
- Subjects
endocrine system ,Pediatrics ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Thyroid disease ,levothyroxine ,Levothyroxine ,congenital hypothyroidism ,virus diseases ,General Medicine ,RC648-665 ,medicine.disease ,Diseases of the endocrine glands. Clinical endocrinology ,Congenital hypothyroidism ,intelligence quotient (iq) ,Medicine ,In patient ,Russian federation ,business ,geographic locations ,hormones, hormone substitutes, and hormone antagonists ,Early onset ,medicine.drug - Abstract
Congenital hypothyroidism – thyroid disease, which occurs approximately 1: 3000-4000 newborns. Early onset of substitution levothyroxine therapy prevents the development of mental retardation. Neonatal screening of сongenital hypothyroidism in Russian Federation was started in 1994. This review presents the data of Russian and foreign researchers about the intellectual outcome of children and adolescents with сongenital hypothyroidism.
- Published
- 2010
- Full Text
- View/download PDF
38. Ozhirenie i vrozhdennyy gipopituitarizm
- Author
-
Ivan Ivanovich Dedov and O B Bezlepkina
- Subjects
ожирение ,гипопитуитаризм ,сахарный диабет ,избыточная масса тела ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Цель. Изучение некоторых показателей жирового обмена у пациентов с врожденным гипопитуитаризмом. Материалы и методы. С целью изучения особенностей жирового обмена была обследована однородная когорта пациентов с врожденной соматотропной недостаточностью, состоящая из 209 пациентов. Уровнилипопротеидов (ОХ, ЛПНП, ЛПОНП, ЛПВП, ТГ) изучены у 176 пациентов (67 женщин, 109 мужчин). Содержание лептина определено у 66 пациентов. Всем пациентам проводилось физикальное обследование с расчетом ИМТ, соотношения ОТ/ОБ по стандартным методикам. Количественный анализ жировой массы (SDS жировой массы), % жировой массы по данным денситометрии определены у 72 пациентов. Проводились денситометрическое исследование (DEXA), двухэнергетическая рентгеновская абсорбциометрия. Результаты. Индекс массы тела был проанализирован у 209 пациентов, избыточный вес, базируясь на данных ИМТ, имели только 12,0% пациентов. Анализ уровня ХС в зависимости от пола выявил, что у женщин его величины были достоверно выше, чем у мужчин. Средний уровень липопротеидов низкой плотности у пациентов с МДГА был достоверно выше. У пациентов с МДГА значения ИА колебались от 0,98 до 10,84. Практически половина пациентов (n=82) имели повышенные значения индекса атерогенности, причем такие значения были характерны как для мужчин, так и для женщин. В результате изучения уровней лептина нами получены данные, свидетельствующие о незначительном нарушении содержания лептина (в сторону его снижения) в сыворотке крови у пациентов с врожденным гипопитуитаризмом. Получены более высокие уровни лептина у женщин по сравнению с мужчинами, в группе пациентов с ИДГР эти различия были достоверными. Выводы. Полученные нами данные позволяют сделать заключение, что ожирение не является характерным симптомом для пациентов с врожденным гипопитуитаризмом. Классическими являются гиперхолестеринемия и дислипидемические нарушения, присущие подавляющему большинству пациентов. Уровни лептина у пациентов с гипопитуитаризмом снижены, сохраняя при этом более высокие уровни у женщин по сравнению с мужчинами.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.